drugset

drugset / Trial / NCT02804399

A Study To Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy Volunteers

NCT02804399 ↗

Phase 1 Completed 12 enrolled Pfizer

CrossoverOpen-labelOther

Summary

The purpose of this study is to estimate the effect of rifampin on the single dose PK of PF-06463922.

Timeline

Start: 2016-07
Primary completion: 2016-10
Completion: 2016-10

Publications

Chen J, Xu H, Pawlak S, James LP, Peltz G, Lee K, Ginman K, Bergeron M, Pithavala YK. The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants. Adv Ther. 2020 Feb;37(2):745-758. doi: 10.1007/s12325-019-01198-9. Epub 2019 Dec 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lorlatinib	Small molecule	100 mg	Oral
Subject	Rifampin	Small molecule	600 mg	Oral

Indications

No indication recorded.